{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:20Z","timestamp":1791475460154,"version":"4.3.4"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eurocalin fund","award":["FP7-HEALTH.2011.1.4.3"],"award-info":[{"award-number":["FP7-HEALTH.2011.1.4.3"]}]},{"name":"Pieris Pharmaceuticals GmbH"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212023","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T20:24:34Z","timestamp":1553718274000},"page":"e0212023","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis"],"prefix":"10.1371","volume":"14","author":[{"given":"Lutz","family":"Renders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rosenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"van Swelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Swinkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dellanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Feuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Erley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-5291","authenticated-orcid":true,"given":"Karoline","family":"Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-4871","authenticated-orcid":true,"given":"Louis","family":"Matis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of Anemia in Chronic Kidney Disease in the United States","volume":"9","author":"ME Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"ref2","first-page":"281","article-title":"National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease","journal-title":"Kidney International Suppl"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2215\/CJN.01420406","article-title":"Acute injury with intravenous iron and concerns regarding long-term safety","volume":"1","author":"K Bishu","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1681\/ASN.2014090922","article-title":"Dialysis Advisory Group of the American Society of Nephrology Considerations and challenges in defining optimal iron utilization in hemodialysis","volume":"26","author":"DM Charytan","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.amjmed.2012.01.015","article-title":"Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study","volume":"125","author":"G Rostoker","year":"2012","journal-title":"Am J Med"},{"issue":"2009","key":"ref6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1681\/ASN.2009040444","article-title":"Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia","volume":"20","author":"AK Singh","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMcibr1112780","article-title":"Closing the Iron Gate","volume":"366","author":"NC Andrews","year":"2012","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and iron homeostasis","volume":"1823","author":"T Ganz","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"14","key":"ref9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2174\/0929867324666170316120538","article-title":"Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond","volume":"24","author":"N Ueda","year":"2017","journal-title":"Curr Med Chem"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1744-9987.12001","article-title":"Hepcidin is a potential regulator of iron status in chronic kidney disease","volume":"17","author":"K Tsuchiya","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"3","key":"ref11","first-page":"108","article-title":"Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker","volume":"73","author":"NC Van der Weerd","year":"2015","journal-title":"PubMed Neth J Med"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcla.21634","article-title":"Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates","volume":"27","author":"JS Troutt","year":"2013","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.seminhematol.2009.06.001","article-title":"Iron sequestration and anemia of inflammation","volume":"46","author":"T Ganz","year":"2009","journal-title":"Semin Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"G. Weiss","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ajh.23110","article-title":"Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation","volume":"87","author":"CC Sun","year":"2012","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0167-4838(00)00145-X","article-title":"Lipocalins as a scaffold","volume":"1482","author":"A Skerra","journal-title":"Biochim Biophys Acta"},{"key":"ref17","first-page":"157","article-title":"Anticalins small engineered binding proteins based on the lipocalin scaffold","volume":"503","author":"M Gebauer","year":"2012","journal-title":"Methods Enzymol"},{"key":"ref18","article-title":"Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey","author":"AM Hohlbaum","year":"2018","journal-title":"Br J Pharmacol"},{"key":"ref19","unstructured":"Cawello W. Parameters for Compartment-free Pharmacokinetics\u2014Standardisation of Study Design, Data Analysis and Reporting. 1999 Shaker Verlag, Aachen, Germany ISBN 3-8265-4767-5"},{"key":"ref20","first-page":"2013","article-title":"Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform","volume":"4","author":"CM Laarakkers","journal-title":"PLOS One"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2010.149187","article-title":"Immunochemical and Mass-Spectrometry\u2013Based Serum Hepcidin Assays for Iron Metabolism Disorders","volume":"56","author":"JC Kroot","year":"2010","journal-title":"Clinical Chemistry"},{"key":"ref22","unstructured":"EMA; Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMEA\/CHMP\/BMWP\/14327\/2006), (April 2008)"},{"issue":"1\u20132","key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the Design and Optimization of Immunoassays used in the Detection of Host Antibodies against Biotechnology Products","volume":"289","author":"AR Mire-Sluis","year":"2004","journal-title":"Journal of Immunological Methods"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the Validation of Immunoassays used for Detection of Host Antibodies against Biotechnology Products","volume":"48","author":"G Shankar","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1159\/000485865","article-title":"Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD)","volume":"42","author":"SW Lee","year":"2017","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3324\/haematol.2016.150433","article-title":"Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model","volume":"102","author":"MR Hanudel","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Torti SV Serum Ferritin: Past, Present and Future","volume":"1800","author":"W Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1373\/clinchem.2012.194977","article-title":"Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations Clinical Chemistry","volume":"59","author":"C Schaap","year":"2013","journal-title":"Clin Chem"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1373\/clinchem.2012.186866","article-title":"Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration","volume":"58","author":"JS Troutt","year":"2012","journal-title":"Clin Chem"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti\u2010hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"M Boyce","year":"2016","journal-title":"Br J Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106 in cancer associated anemia","volume":"10","author":"A Vadhan-Raj","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.24178","article-title":"Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice","volume":"53","author":"E Ramos","year":"2011","journal-title":"Hepatology"},{"issue":"17","key":"ref33","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2015-05-642223","article-title":"Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women","volume":"126","author":"D Moretti","year":"2015","journal-title":"Blood"},{"key":"ref34","article-title":"Unraveling the Effect of Immunogenicity on the PK\/PD, Efficacy, and Safety of Therapeutic Proteins","volume":"201","author":"A Smith","journal-title":"Journal of Immunology Research"},{"key":"ref35","unstructured":"FDA Guidance for Industry (2014) Immunogenicity Assessment for Therapeutic Protein Products <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fda.gov\/downloads\/\u2026\/Guidances\/UCM192750.pdf\" xlink:type=\"simple\">https:\/\/www.fda.gov\/downloads\/\u2026\/Guidances\/UCM192750.pdf<\/ext-link>"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of Immune Dysfunction in End-stage Renal Disease","volume":"3","author":"S Kato","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:58:06Z","timestamp":1588993086000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212023"}},"subtitle":[],"editor":[{"given":"Kathrin","family":"Eller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212023","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]}}}